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Abstract G protein coupled receptor kinase type 2 (GRK2)
plays an important role in the development and maintenance
of cardiac hypertrophy and heart failure even if its exact role is
still unknown. In this study, we assessed the effect of GRK2
on the regulation of cardiac hypertrophy. In H9C2 cells,
GRK2 overexpression increased atrial natriuretic factor
(ANF) activity and enhanced phenylephrine-induced ANF re-
sponse, and this is associated with an increase of NFκB tran-
scriptional activity. The kinase dead mutant and a synthetic
inhibitor of GRK2 activity exerted the opposite effect, sug-
gesting that GRK2 regulates hypertrophy through upregula-
tion of NFκB activity in a phosphorylation-dependent manner.
In two different in vivo models of left ventricle hypertrophy
(LVH), the selective inhibition of GRK2 activity prevented
hypertrophy and reduced NFκB transcription activity. Our
results suggest a previously undisclosed role for GRK2 in
the regulation of hypertrophic responses and propose GRK2
as potential therapeutic target for limiting LVH.
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Introduction
G protein coupled receptor (GPCR) kinases (GRKs) are
serine/threonine kinases which regulate the activity of GPCR
through phosphorylation [1]. Changes in GRK activity and
expression have been shown to play an important role in the
development and maintenance of cardiac hypertrophy and
heart failure [2–4] even if their exact role remains to be eluci-
dated. In particular, GRK2 is known to be regulated in several
cardiovascular disorders since increased levels of GRK2 are
observed during left ventricular hypertrophy (LVH) [3, 4, 5, 6,
7] and are associated with an impaired cardiac contractility via
reduction of beta adrenergic receptor inotropic response [2].
As to the mechanistic role of GRK2 in the heart, it has been
shown that, besides βAR downregulation and desensitization,
GRK2 can engage with different intracellular partners to reg-
ulate several cardiomyocyte functions. Indeed, this kinase in-
duces cardiac insulin resistance and reduces cardiac metabolic
plasticity [8], regulates mitochondrial function [9, 10], and
participates to intracellular calcium homeostasis [11]. Given
its molecular and functional complexity, it is not surprising
that this molecule has a pivotal role in regulating both function
and development of cardiovascular system. Indeed, global
genetic deletion of GRK2 is lethal by preventing the correct
development of cardiovascular system in prenatal life [12] and
in adult life the selective cardiac deletion of GRK2 leads to a
prevalent eccentric remodeling after chronic exposure to β
adrenergic stimulation [13]. This evidence suggests that
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GRK2 might participate to the hypertrophic responses of the
injured adult heart.
The molecular mechanisms underlying LVH comprise the
activation of several transcription factors, such as MEF-2,
GATA-4, and NFAT [14–18]. Recently, nuclear factor-κB
(NFκB) has also been associated with the development of
cardiac hypertrophy [19, 20]. Indeed, NFκB has been demon-
strated to be relevant in the pathophysiology of LVH and
remodeling throughmechanisms independent from inflamma-
tion [21]. NFκB mediates hypertrophic growth of
cardiomyocytes in response to G protein coupled receptor
(GPCR) agonists, including norepinephrine, endothelin-1,
and angiotensin-II [22, 23]. Additionally, NFκB inhibition
has been shown to attenuate LVH in different animal models
[24, 25]. This evidence suggests that NFκB blockade may be
an effective strategy to counteract LVH and cardiac remodel-
ing [25, 26].
Based on such a background, the aim of this study is to
evaluate the role of GRK2 in the development of LVH both
in vitro and in vivo and whether such phenomenon is associ-




A cell line of cardiac myoblasts (H9C2), which is a well-
established model of hypertrophy in vitro [27–30], was main-
tained in culture in DMEM supplemented with 10 % FBS at
37 °C in 95 % air–5 % CO2.
Luciferase Assay
Cells were transfected with plasmid expression vectors con-
taining the luciferase reporter gene linked to five repeats of an
NFκB binding site (κB-Luc) or atrial natriuretic factor (ANF)
promoter. Lysates were analyzed using the luciferase assay
system with reporter lysis buffer from Promega.
Immunoprecipitation and Western Blot
Cells were lysed in RIPA/sodium dodecyl sulfate (SDS) buff-
er. Endogenous IκBα or GRK2 from total extracts were
immunoprecipitated with specific antibodies (Santa Cruz)
and protein A/G agarose (Santa Cruz). After extensive wash-
ing, the immunocomplexes were electrophoresed by SDS/
PAGE and transferred to nitrocellulose. For western blot anal-
ysis, the experiments were performed as described previously
[25, 31, 32].
Electrophoretic Mobility Shift Assay
Nuclear proteins were isolated from heart samples, and NFκB
binding activity was examined by electrophoretic mobility
shift assay, as described previously [31, 33].
In Vivo Study
Experiments were carried out on 12-week-old normotensive
Wistar Kyoto (WKY) and spontaneously hypertensive male
rats (Charles River, Calco, LC, Italy). Four injections (50 μL
each) of Ant-124 (10−4 M) or Ant as control, into the cardiac
wall, were performed once a week for 3 weeks. In the WKY
group, after cardiac injection, we implanted subcutaneously a
miniosmotic pump (ALZET 2004) releasing phenylephrine
(PE) (100 mg/kg).
Echocardiography
Transthoracic echocardiography was performed at days 0, 7,
14, and 21 after surgery using a dedicated small-animal high-
resolution imaging system (VeVo 770, Visualsonics, Inc).
Isolation of Ventricular Cardiomyocytes and Real-Time
PCR
Adult mouse ventricular myocytes were isolated from
GRK2fl/fl mice hearts by a standard enzymatic digestion pro-
cedure as previously described [34]. Total RNAwas isolated
and real-time quantitative PCR was performed.
Statistical Analysis
All data are presented asmean±SEM. Two-wayANOVAwith
a Bonferroni post hoc test was performed to compare the
different parameters between the different groups. A p value
<0.05 was considered significant. Statistical analysis was per-
formed using GraphPad Prism version 5.01 (GraphPad Soft-
ware, Inc., San Diego, CA).
Results
GRK2 Induces Hypertrophy In Vitro
To evaluate the ability of GRK2 to modulate hypertrophy
in vitro, we performed an ANF-promoter-driven luciferase
assay to evaluate ANF promoter activity and real-time PCR
to evaluate ANF gene expression. In H9C2, the overexpres-
sion of GRK2 was performed by transient transfection, and
hypertrophy was induced by stimulation with phenylephrine
(PE). GRK2 overexpression increased ANF promoter activity
(Fig. 1a) and ANF gene expression (Fig. 1b) and enhanced the
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response to PE. To confirm this finding, we also evaluated
BNP gene expression, another marker of hypertrophy, by
real-time PCR. GRK2 overexpression increased BNP gene
expression and enhanced the response to PE (Supplementary
Fig. S1). To evaluate whether the catalytic activity of GRK2 is
needed to induce such phenomenon, we overexpressed in cells
the kinase dead mutant of GRK2 (GRK2-DN). Overexpres-
sion of GRK2-DN inhibited ANF promoter activity (Fig. 1a)
and ANF gene expression (Fig. 1b) both basally and in re-
sponse to PE, opposite to the naive kinase. Similar results
were found in the regulation of BNP gene expression (Sup-
plementary Fig. S1). To further support these data, we treated
cells with a previously described peptide inhibitor of GRK2,
Ant-124 [35]. As expected, Ant-124 inhibits the catalytic ac-
tivity of GRK2 in cardiomyoblasts (Fig. 1c). Interestingly, the
treatment with Ant-124 inhibited both PE- and GRK2-
induced ANF promoter activity (Fig. 1d) and ANF gene ex-
pression (Fig. 1e) compared with Ant. To evaluate whether
GRK2 inhibition was effective also in response to other hy-
pertrophic stimuli, besides alpha-adrenergic activation, we
evaluated ANF gene expression in response to angiotensin
II. The inhibition of GRK2 was effective also in response to
angiotensin II (Supplementary Fig. S2).
GRK2 Induces Hypertrophy by Regulating NFκB
Activity
In other cell types, GRK2 deletion or overexpression recipro-
cally regulates TNFα-induced IκBα phosphorylation and
degradation and consequent regulation of NFκB [36]. Thus,
Fig. 1 GRK2 regulates
hypertrophy in vitro (a–e). To
assess the role of GRK2 in
hypertrophy, we evaluated ANF
promoter activity by luciferase
assay and ANF gene expression
by real-time PCR. H9C2 cells
were transfected with an empty
plasmid (CTRL) and a plasmid
encoding GRK2 or GRK2-DN.
The overexpression of GRK2
induces ANF promoter activity
(a) and ANF gene expression (b)
both basally and in response to
PE. The overexpression of a
kinase dead mutant of GRK2
inhibits ANF promoter activity in
response to PE with respect to the
wild type form of GRK2. To
confirm such finding, we use a
synthetic inhibitor of GRK2,
Ant-124, that specifically inhibits
its kinase activity (c). Ant-124
significantly inhibits ANF
promoter activity (d) and ANF
gene expression (e) in response to
PE and following GRK2
overexpression (d). The scramble
peptide Ant was used as control.
Results are the mean of five
independent experiments.
*p<0.05 versus untreated CTRL;
#p<0.05 versus PE-CTRL;
§p<0.05 versus GRK2
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we evaluated the possibility that GRK2 could regulate the
activation of NFκB signaling also in H9C2. To this aim, we
first confirmed that GRK2 regulates IκBα levels. Indeed,
overexpression of GRK2 reduced IκBα levels while GRK2-
DN has no effects (Fig. 2a). We then evaluated if GRK2 was
able to interact with and phosphorylate IκBα as previously
demonstrated for GRK5 [31]. Figure 2b shows that GRK2 co-
precipitates with IκBα in whole cell lysates, and results of the
kinase assay with purified proteins shows that GRK2 is also
able to phosphorylate IκBα (Fig. 2c). Consistently, the over-
expression of GRK2-WT increased NFκB activity both basal-
ly and in response to PE; GRK2-DN and Ant-124 reduced
Fig. 2 GRK2 induces hypertrophy by regulating NFκB activity. a In
whole cell lysates from H9C2, IκBα levels were analyzed by
immunoblot. The overexpression of GRK2 reduces total levels of IκBα
while the kinase deadmutant does not modify IκBα levels with respect to
control. Actin was used as loading control and GRK2 levels were
evaluated to verify whether transfection occurred. Images are
representative of three independent experiments. b The ability of GRK2
to precipitate IκBα was evaluated by co-immunoprecipitation and
western blot. GRK2 is able to precipitate IκBα and the overexpression
of the kinase enhances such binding while GRK2DN has no effect.
Images are representative of three independent experiments. c To assess
the ability of GRK2 to phosphorylate IκBα, we performed a kinase
activity assay. GRK2 is able to phosphorylate itself and to
phosphorylate IκBα. IκBα alone was used as negative control. Images
are the result of three independent experiments. d To evaluate whether
GRK2 could regulate NFκB activity, we performed a luciferase assay.
GRK2 is able to induce NFκB activity both basally and in response to PE
while both GRK2-DN and Ant-124 prevent such activation. The
scramble peptide Ant was used as control. Results are the mean of five
independent experiments. *p<0.05 versus CTRL; #p<0.05 versus PE. e
We evaluated the effects of an inhibitor of NFκB, IκBα, on GRK2-
dependent ANF promoter activity in response to PE. The
overexpression of IκBα inhibited PE-induced ANF promoter activity
both basally and in response to GRK2 overexpression. Results are the
mean of five independent experiments. *p<0.05 versus CTRL; #p<0.05
versus PE
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such response (Fig. 2d). To confirm that GRK2 regulates hy-
pertrophic responses by inducing NFκB activity, we evaluated
the effects of an inhibitor of NFκB, IκBα, on GRK2-
dependent ANF promoter activity in response to PE. The
overexpression of IκBα inhibited PE-induced ANF promoter
activity both basally and in response to GRK2 overexpression
(Fig. 2e). Altogether, these data suggest that GRK2 can regu-
late hypertrophic responses in vitro by modulating NFκB ac-
tivity through the phosphorylation of IκBα.
The Knockdown of GRK2 Reduces Hypertrophic
Responses by Inhibiting NFκB Activity
In order to confirm the involvement of GRK2 in the regulation
of hypertrophic phenotypes in vitro, we evaluated the effects
of GRK2 knockdown on ANF gene expression in response to
PE. In H9C2 cells, the knockdown of GRK2 was induced by
means of a specific siRNA, as previously described [10], lead-
ing to a significant reduction of GRK2 expression with respect
to the transfection of a scramble siRNA (Fig. 3a). GRK2
knockdown is associated with a significant increase of IκB
levels (Fig. 3a) and a reduction of ANF gene expression in
response to PE (Fig. 3b). These data confirmed the key role of
GRK2 in the development of PE-induced hypertrophic phe-
notype in vitro.
GRK2 Regulates the Hypertrophic Phenotype in SHR
Rats
To confirm the physiological relevance of the in vitro results, we
evaluated the role of GRK2 in the development of cardiac hy-
pertrophy in spontaneously hypertensive (SHR) rats, an animal
model of hypertension-induced LVH. To this aim, the inhibitor
of GRK2, Ant-124, or the scramble peptide, Ant, was injected
in the cardiac wall of SHR, and echocardiographic analysis was
performed weekly to evaluate the progression of hypertrophy
(Supplementary Fig. S3). At the end of the treatment (21 days),
left ventricular mass (LVM) was enhanced in SHR with respect
to WKY and the treatment with Ant-124 significantly reduced
such values (Fig. 4a). A physiological reduction of the left ven-
tricular end diastolic diameter (LVEDD) was observed in SHR
comparedwithWKY,which was recovered in SHR treatedwith
Ant-124 (Fig. 4b). Intraventricular septal (IVS) was thicker in
SHR and the treatment with Ant-124 reduced such value
(Fig. 4c). This is associatedwith an ameliorated cardiac function
in SHR treated with Ant-124 compared with controls (Fig. 4d).
The analysis of echocardiographic parameters show that SHR is
a model of concentric hypertrophy, according the Knoll et al.
paper [37], and that the inhibition of the catalytic activity of
GRK2 in this model protects from left ventricular hypertrophy
suggesting that this kinase is deleterious in the development of
such pathological condition. Indeed, GRK2 levels in hearts
from SHR are significantly higher with respect to WKY and
were partially reduced by the treatment with Ant-124 (Fig. 4e).
To confirm that GRK2-dependent LVH is strictly associated
with the ability of the kinase to regulate NFκB activity, we
evaluated NFκB activity by EMSA in hearts from control and
treated SHR. Figure 4f shows that NFκB activity was enhanced
in SHR hearts with respect toWKYand the treatment with Ant-
124 significantly reduced such activation.
GRK2 Is Involved in the Development
of the Hypertrophic Phenotype in WKY Rats
The SHR model of hypertrophy suggests that GRK2 is in-
volved in the progression of cardiac hypertrophy. To assess
whether GRK2 is involved in the development of LVH,WKY
rats were treated with intramyocardial injection of Ant-124 or
Ant before inducing hypertrophy by chronic administration of
PE (14 days) using mini-osmotic pumps. Echocardiographic
analysis was performed at the end of the treatment to evaluate
the progression of hypertrophy (Supplementary Fig. S4). Ac-
cording the Knoll et al. paper [37], WKY rats treated with
chronic infusion of PE present a concentric hypertrophy since
there is an increase of cardiac size (Fig. 5a) and IVS (Fig. 5b)
and a reduction of LVEDD (Fig. 5c). Ant-124 prevented the
Fig. 3 The knockdown of GRK2 reduces hypertrophic responses by
inhibiting NFκB activity. a, b In H9C2 cells, the knockdown of GRK2
was induced by means of a specific siRNA. Control and PE were treated
with a scramble siRNA. GRK2 and IκB levels were evaluated by
immunoblot. GRK2 downregulation, confirmed by the reduction of
GRK2 expression respect to the scramble transfection (CTRL),
associates with an increase of IκB levels (a). GRK2 knockdown causes
a reduction of ANF gene expression in response to PE, evaluated by real-
time PCR (b). *p<0.05 versus CTRL; #p<0.05 versus PE
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progression of cardiac hypertrophy since both LVM (Fig. 5a)
and IVS (Fig. 5b) were reduced in PE-treated rats with respect
to controls and LVEDD was recovered (Fig. 5c). These data
suggest that the inhibition of GRK2 activity prevents PE-
induced cardiac hypertrophy. To confirm this result, we eval-
uated IκBα levels in hearts collected from treated rats.
Figure 5c shows that the inhibition of GRK2 activity increased
IκBα levels both basally and in response to PE. GRK2 levels
were increased in response to PE and reduced by the treatment
with Ant-124 (Fig. 5c).
The Knockdown of GRK2 Inhibits Cardiac Hypertrophy
In Vivo
Hypertrophy was induced in GRK2fl/fl mice through means of
implantation of miniosmotic pumps which gradually release
PE. A group of mice was treated with an intracardiac injection
of an adenovirus coding for CRE recombinase (the enzyme
that catalyzes site-specific recombination of DNA between
two loxP sites) to induce GRK2 knockout in the heart, con-
firmed by immunoblot (Fig. 6a). Echocardiographic
Fig. 4 The inhibition of GRK2
by Ant-124 activity reduces
hypertrophy in SHR. a–d SHR
rats were treated with Ant-124 or
the scramble peptide Ant by
intramyocardial injection, and
echocardiographic parameters
were evaluated to analyze the
effect of Ant-124 on the
progression of cardiac
hypertrophy. At the end of the
treatment, LVM (a) was
significantly reduced in rats
treated with Ant-124 compared
with those treated with Ant. A
reduction of LVEDD was
observed in SHR compared with
WKY, which was recovered in
SHR treated with Ant-124 (b).
IVS (c) was enhanced in SHR rats
and reduced by Ant-124.
Accordingly, cardiac function
was enhanced in treated rats (d).
*p<0.05 versus WKY; #p<0.05
versus SHR vehicle. e GRK2
levels were evaluated by
immunoblot in hearts from the
different groups. GRK2 levels
increased in SHR with respect to
WKY, and the treatment with
Ant-124 reduced such effect. f
Nuclear extracts were prepared
from collected hearts, and NFκB
activity was evaluated by EMSA.
The ability of NFκB to bind DNA
was significantly increased in
SHR with respect to WKY, and
Ant-124 treatment prevented such
an increase. Densitometric
analysis is shown in graph.
*p<0.05 versus WKY; #p<0.05
versus SHRVehicle. NC negative
control
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parameters were evaluated after 2 weeks from starting treat-
ment. In particular, IVS (Fig. 6b) and LVM (Fig. 6c) were
reduced in CRE-treated GRK2fl/fl mice with respect to control
GRK2fl/fl mice in response to PE. Accordingly, PE-induced
impairment of cardiac function was restored by GRK2 knock-
down (Fig. 6d), and this is associated with a reduction of ANF
gene expression in cardiac myocytes (Fig. 6e).
Discussion
Our study produces three steps forward in the knowledge of
the molecular basis of LVH leading to the identification of
new targets for therapeutic treatments. First of all, we identify
a new cytosolic substrate of GRK2 in the heart, IκBα. Second,
we demonstrate that GRK2-dependent regulation of NFκB
transcription activity contributes to the development of LVH.
Third, our study proposes a new therapeutic strategy for the
treatment of LVH based on the downregulation of the expres-
sion levels of GRK2 or the specific inhibition of its catalytic
activity by a new small molecule, Ant-124.
Our data identify a new non-canonical role of GRK2 in the
heart which is based on the phosphorylation of a novel cyto-
solic partner, IκBα, leading to the regulation of hypertrophy-
related gene expression. Thus, the present study defines a new
role of GRK2 in cardiac hypertrophy and identifies NFκB as
the intrinsic mechanism. The ability to regulate transcription
factors in hypertrophy has been recently demonstrated for
GRK5 [38] which, by acting in a kinase-independent manner,
regulates NFAT activity and LVH [38]. Here we demonstrate
for the first time that also GRK2 participates to the setting of
the hypertrophic phenotype through the regulation of NFκB.
This latter is not a specific cardiac transcription factor, but its
involvement in the regulation of LVH is extensively demon-
strated [25]. Indeed, we demonstrated that NFκB activity is
enhanced in LVH and its inhibition prevents the development
of cardiac hypertrophy and ameliorates cardiac function [25].
Here we show that GRK2 is able to bind and phosphorylate
IκBα, the NFκB inhibitor, leading to the activation of NFκB
transcriptional activity and consequently to the increase of the
hypertrophic gene expression, ANF. This effect is abolished
byGRK2 knockdown both in vitro and in vivo. The activity of
Fig. 5 Ant-124 inhibits the development of PE-induced hypertrophy. a–
d WKY rats were treated with Ant-124 or Ant by intramyocardial
injection, and then hypertrophy was induced through infusion of PE by
osmotic pumps. Echocardiographic parameters were evaluated to analyze
the effect of Ant-124 on the development of cardiac hypertrophy. Both
LVM (a) and IVS (b) were significantly reduced in rats treated with Ant-
124 compared with those treated with Ant. A reduction of LVEDD (c)
was observed in WKY treated with PE compared with controls that was
recovered by the treatment with Ant-124. *p<0.05 versus untreated;
#p<0.05 versus PE vehicle. d IκBα and GRK2 levels were evaluated in
hearts collected from treated rats. IκBα levels were increased in treated
hearts in response to PE. GRK2 levels were increased in response to PE
and reduced by the treatment. Actin was used as loading control. Results
are the mean of five independent experiments
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the kinase is needed to regulate hypertrophic phenotypes. In-
deed, in different animal models of hypertrophy (hyperten-
sion-induced hypertrophy in SHR and PE-induced hyper-
trophy in WKY), pharmacological inhibition of GRK2 cat-
alytic activity through a synthetic inhibitor, Ant-124, re-
duces LVH. It has already been described that the inhibition
of GRK2 activity is advantageous for the treatment of car-
diovascular diseases, such as heart failure [39], but it has
never been shown in LVH and never with a pharmacolog-
ical inhibitor. Until now, the inhibition of GRK2 activity
was induced by means of a GRK2 truncated mutant con-
taining the carboxy-terminal domain of the kinase (GRK2-
ct), which really acts as a scavenger of GRK2 from plasma
membrane rather than an inhibitor of the kinase activity.
Here, we used a small peptide that is more selective than
GRK2-ct since it specifically binds the HJ loop of GRK2
catalytic domain leading to the selective inhibition of the
kinase activity [35] without affecting other pathways which
are independent from GRK2. This latter aspect is advanta-
geous for a therapeutic treatment since the effects of GRK2-
ct depends on its interaction with Gβγ which causes not
only the inhibition of GRK2 signaling on plasma mem-
brane but also the inhibition of specific Gβγ signaling.
GRK2-ct bears therefore the ability to interact with other
several signal transduction pathways within the cell, such
as MAPK and PI3K signaling, increasing the possibility of
undesired effects.
In conclusion, our results suggest a novel role of GRK2
in the regulation of hypertrophy both in vitro and in vivo
that is in accord with recent literature which shows that
GRK2 downregulation/inhibition is useful to ameliorate
cardiac function in pathological conditions, such as insulin
resistance, diabetes, or obesity [40]. Moreover, here we
propose the downregulation of GRK2 levels or the inhibi-
tion of its catalytic activity as a new strategy to ameliorate
cardiac function in hypertrophy. In particular, we propose
Fig. 6 The knockdown of GRK2
inhibits cardiac hypertrophy
in vivo. a GRK2fl/fl mice were
treated with PE, and an
intramyocardial injection of an
adenovirus coding for CRE or an
empty adenovirus as control was
performed to induce GRK2
knockout in the heart, as assessed
by immunoblot analysis. b–d
Echocardiographic parameters
were evaluated after 2 weeks from
starting treatment. IVS (b) and
LVM (c) were reduced in CRE-
treated GRK2fl/fl mice with
respect to control GRK2fl/fl mice
in response to PE. Accordingly,
PE-induced impairment of
cardiac function was restored by
GRK2 silencing (d). *p<0.05
versus CTRL; #p<0.05 versus PE
Vehicle. e Cardiac myocytes were
collected from hearts of GRK2fl/fl
mice treated with CRE and PE.
ANF gene expression was
evaluated by real-time PCR. The
cardiac knockout of GRK2 in
GRK2fl/fl mice treated with CRE
reduced ANF gene expression in
response to PE compared with
controls. *p<0.05 versus CTRL;
#p<0.05 versus PE vehicle
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Ant-124 as a pro to type for the genera t ion of a
pharmacophore to use for therapeutic applications for the
treatment of LVH.
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